{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:20:58Z","timestamp":1794860458698,"version":"4.9.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate 12-month outcomes after systematic switch to aflibercept 8 mg in previously treated eyes with neovascular age-related macular degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Eyes in a plateau phase (\u226510 prior anti-vascular endothelial growth factor injections) that were switched to aflibercept 8 mg were retrospectively evaluated. Treatment intervals, best-corrected visual acuity (BCVA), central retinal thickness, and data on intraretinal fluid or subretinal fluid were assessed at switch and after 3, 6, and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 654 eyes from 567 patients were included (mean [SD] age 82.4 [7.4], 34.5 [21.5] injections per eye before switch). The proportion of eyes with dry maculae increased from 55% at switch to 76% at 3 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), 73% at 6 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and 69% at 12 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Eyes treated at 3\u20135-week intervals declined from 46% at switch to 18% at 12 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Eyes on 9\u201312-week intervals increased from 11% to 34% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The mean treatment interval increased from 6.0 (2.1) to 7.8 (2.4) weeks (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Eyes with dry maculae at switch were extended by 2.6 (1.8) weeks (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The mean central retinal thickness decreased from 234.7 (49.7) to 223.5 (46.7)\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). BCVA declined from 68.5 (12.2) to 67.3 (13.9) early treatment diabetic retinopathy study letters in the overall cohort, and from 68.5 (12.3) to 66.6 (14.3) early treatment diabetic retinopathy study letters in eyes with a dry macula at switch (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Switching to aflibercept 8 mg improved anatomical outcomes and reduced the proportion of eyes on short intervals. A slight decline in BCVA was observed, warranting long-term follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004888","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T21:00:09Z","timestamp":1779829209000},"page":"2215-2222","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["REAL-WORLD OUTCOMES AFTER SWITCH TO AFLIBERCEPT 8 MG IN NEOVASCULAR AMD"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3555-5511","authenticated-orcid":false,"given":"Celine","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;"},{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary G.","family":"Karunainathan","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;"},{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaweh D.","family":"Zohalinejad","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads O.","family":"M\u00e6ng","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;"},{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna W.","family":"Fabrin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren K.","family":"Yde","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren K.","family":"Abildgaard","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Vorum","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif","family":"Subhi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark; and"},{"name":"Department of Clinical Research, University of Southern Denmark, Odense, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"\u00d8rskov","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;"},{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse J.","family":"Cehofski","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;"},{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark;"},{"name":"Retina Consultants of Texas, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261116","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R2-20261116","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/DDDT.S40215","article-title":"Aflibercept in wet AMD: specific role and optimal use","volume":"7","author":"Semeraro","year":"2013","journal-title":"Drug Des Dev Ther"},{"key":"R3-20261116","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"R4-20261116","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","article-title":"Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial","volume":"41","author":"Mitchell","year":"2021","journal-title":"Retina"},{"key":"R5-20261116","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bjophthalmol-2020-317434","article-title":"Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence","volume":"105","author":"Daien","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R6-20261116","doi-asserted-by":"crossref","first-page":"e0129361","DOI":"10.1371\/journal.pone.0129361","article-title":"Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration","volume":"10","author":"Gohil","year":"2015","journal-title":"PLoS One"},{"key":"R7-20261116","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R8-20261116","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet (London, England)"},{"key":"R9-20261116","doi-asserted-by":"crossref","first-page":"100179","DOI":"10.1016\/j.ajoint.2025.100179","article-title":"Inflammation and increased intraocular pressure associated with intravitreal aflibercept 8 mg: a systematic review","volume":"2","author":"Rebsdorf","year":"2025","journal-title":"AJO Int"},{"key":"R10-20261116","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/11206721241310628","article-title":"Real-world evidence of anti-VEGF therapies in patients with neovascular age-related macular degeneration in Italy: the RADIANCE study","volume":"35","author":"Parravano","year":"2025","journal-title":"Eur J Ophthalmol"},{"key":"R11-20261116","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ophtha.2020.02.027","article-title":"Management and outcomes for neovascular age-related macular degeneration","volume":"127","author":"Kiss","year":"2020","journal-title":"Ophthalmology"},{"key":"R12-20261116","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/aos.16709","article-title":"Injection burden and treatment intervals of aflibercept in observe\u2010and\u2010plan regimen for neovascular age\u2010related macular degeneration","volume":"102","author":"Subhi","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"R13-20261116","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/life15060903","article-title":"Early real-world outcomes of switching to 8 mg aflibercept for neovascular age-related macular degeneration in the United Kingdom","volume":"15","author":"Musadiq","year":"2025","journal-title":"Life"},{"key":"R14-20261116","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/aos.17590","article-title":"Real\u2010world outcomes of aflibercept 8 mg in patients previously treated for neovascular age\u2010related macular degeneration","volume":"104","author":"Ishkheidem","year":"2026","journal-title":"Acta Ophthalmol"},{"key":"R15-20261116","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.oret.2025.02.002","article-title":"Initial functional and anatomical outcomes of high-dose aflibercept 8 mg in exudative neovascular age-related macular degeneration","volume":"9","author":"Bala","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"R16-20261116","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"},{"key":"R17-20261116","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12886-025-04212-7","article-title":"Real-world outcomes of a loading phase with intravitreal faricimab in refractory neovascular age-related macular degeneration (nAMD) patients","volume":"25","author":"Yufeng","year":"2025","journal-title":"BMC Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:01:41Z","timestamp":1794859301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004888"}},"subtitle":["Twelve Months Follow-up on 654 Eyes"],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004888","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,12]]}}}